Assessing the Risk and Potential of Relay Therapeutics Inc’s (RLAY) Stock

The stock of Relay Therapeutics Inc (RLAY) has seen a -5.68% decrease in the past week, with a -29.66% drop in the past month, and a -39.77% decrease in the past quarter. The volatility ratio for the week is 5.86%, and the volatility levels for the past 30 days are at 5.95% for RLAY. The simple moving average for the last 20 days is -16.52% for RLAY stock, with a simple moving average of -26.99% for the last 200 days.

Is It Worth Investing in Relay Therapeutics Inc (NASDAQ: RLAY) Right Now?

The 36-month beta value for RLAY is at 1.64. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The public float for RLAY is 92.21M, and currently, shorts hold a 12.81% of that float. The average trading volume for RLAY on April 04, 2024 was 1.10M shares.

RLAY) stock’s latest price update

Relay Therapeutics Inc (NASDAQ: RLAY)’s stock price has decreased by -6.05 compared to its previous closing price of 7.60. However, the company has seen a -5.68% decrease in its stock price over the last five trading sessions. InvestorPlace reported 2024-03-15 that Now might be a great time for investors to consider investing in precision medicine stocks. For those who don’t know, precision medicine is an approach to disease treatment and prevention that tailors medical decisions to the individual patient.

Analysts’ Opinion of RLAY

Many brokerage firms have already submitted their reports for RLAY stocks, with Jefferies repeating the rating for RLAY by listing it as a “Hold.” The predicted price for RLAY in the upcoming period, according to Jefferies is $12.50 based on the research report published on April 20, 2023 of the previous year 2023.

Raymond James, on the other hand, stated in their research note that they expect to see RLAY reach a price target of $29. The rating they have provided for RLAY stocks is “Strong Buy” according to the report published on April 19th, 2023.

Raymond James gave a rating of “Outperform” to RLAY, setting the target price at $29 in the report published on April 13th of the previous year.

RLAY Trading at -23.14% from the 50-Day Moving Average

After a stumble in the market that brought RLAY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -62.87% of loss for the given period.

Volatility was left at 5.95%, however, over the last 30 days, the volatility rate increased by 5.86%, as shares sank -27.88% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -30.14% lower at present.

During the last 5 trading sessions, RLAY fell by -5.68%, which changed the moving average for the period of 200-days by -44.18% in comparison to the 20-day moving average, which settled at $8.41. In addition, Relay Therapeutics Inc saw -35.15% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at RLAY starting from Bergstrom Donald A, who sale 765 shares at the price of $7.70 back on Mar 27 ’24. After this action, Bergstrom Donald A now owns 530,113 shares of Relay Therapeutics Inc, valued at $5,890 using the latest closing price.

Catinazzo Thomas, the Chief Financial Officer of Relay Therapeutics Inc, sale 348 shares at $7.70 during a trade that took place back on Mar 27 ’24, which means that Catinazzo Thomas is holding 341,498 shares at $2,680 based on the most recent closing price.

Stock Fundamentals for RLAY

Current profitability levels for the company are sitting at:

  • -14.6 for the present operating margin
  • 0.79 for the gross margin

The net margin for Relay Therapeutics Inc stands at -13.11. The total capital return value is set at -0.46. Equity return is now at value -40.18, with -35.19 for asset returns.

Based on Relay Therapeutics Inc (RLAY), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -5.62.

Currently, EBITDA for the company is -380.57 million with net debt to EBITDA at 0.24. When we switch over and look at the enterprise to sales, we see a ratio of 33.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 25.44.


In conclusion, Relay Therapeutics Inc (RLAY) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts